EMEA-001030-PIP01-10-M05

  • Email
  • Help

Overview

Product details for Invokana
Invented nameInvokana
Active substance

Canagliflozin

Decision numberP/0019/2016
PIP numberEMEA-001030-PIP01-10-M05
Pharmaceutical form(s)Tablet
Condition(s)/indication(s)

Treatment of type-2 diabetes mellitus

Route(s) of administrationOral use
PIP applicant

Janssen-Cilag International N.V.
Belgium
Tel. +33 5500 4066
Fax +32 1460 6377
E-mail: ihammer@its.jnj.com

Decision typePM: decision on the application for modification of an agreed PIP

Decision

Name Language First published Last updated
P/0019/2016: EMA decision of 29 January 2016 on the acceptance of a modification of an agreed paediatric investigation plan for canagliflozin (Invokana), (EMEA-001030-PIP01-10-M05) (English only) 2016-03-29